Mariette E. Botes

Learn More
BACKGROUND Human immunodeficiency virus type 1 (HIV-1) drug resistance may limit the benefits of antiretroviral therapy (ART). This cohort study examined patterns of drug-resistance mutations (DRMs) in individuals with virological failure on first-line ART at 13 clinical sites in 6 African countries and predicted their impact on second-line drug(More)
y These authors contributed equally to this work and share joint first authorship z See Appendix 1 for institutional affiliations How did the study come about? According to World Health Organization (WHO) estimates , 33.4 million people were infected with the human immunodeficiency virus (HIV) type 1 globally at the end of 2008. 1 Sub-Saharan Africa and(More)
Human immunodeficiency virus (HIV) RNA testing and HIV drug resistance (HIVDR) testing are not routinely available for therapeutic monitoring of patients receiving antiretroviral therapy (ART) in resource-limited settings. World Health Organization HIVDR early warning indicators (EWIs) assess ART site factors known to favor the emergence of HIVDR. HIV drug(More)
OBJECTIVE Maraviroc, a chemokine co-receptor type 5 (CCR5) antagonist, has demonstrated comparable efficacy and safety to efavirenz, each in combination with zidovudine/lamivudine, over 96 weeks in the Maraviroc vs. Efavirenz Regimens as Initial Therapy (MERIT) study. Here we report 5-year findings. DESIGN A randomized, double-blind, multicenter phase(More)
The PharmAccess African Studies to Evaluate Resistance (PASER) network was established as a collaborative partnership of clinical sites, laboratories, and research groups in 6 African countries; its purpose is to build research and laboratory capacity in support of a coordinated effort to assess population-level acquired and transmitted human(More)
  • T Sonia Boender, Bernice M Hoenderboom, +13 authors Tobias F Rinke de Wit
  • 2015
BACKGROUND After the scale-up of antiretroviral therapy (ART) for human immunodeficiency virus (HIV) infection in Africa, increasing numbers of patients have pretreatment drug resistance. METHODS In a large multicountry cohort of patients starting standard first-line ART in six African countries, pol genotyping was retrospectively performed if viral load(More)
Donor funds are available for treatment of many diseases such as HIV. However, privacy constraints make it hard for donor organisations to verify that they have not sponsored the same patient twice — or sponsored a patient whose treatment was also sponsored by another donor. This paper presents a protocol based on digital cash that enables donor(More)
  • 1